Table 2.

ORs for incidence of breast cancer in relation to quartiles of plasma DHEA (ng/mL) or DHEAS (μg/mL) among women not currently using menopausal hormone replacement therapy.

Plasma hormone levels, quartilesa
1st2nd3rd4th
N cases/controlsOR (95% CI)OR (95% CI)OR (95% CI)OR (95% CI)P value trendb
Premenopausal women
DHEA
Model 1153/2801.01.09 (0.62–1.94)0.89 (0.49–1.59)1.03 (0.58–1.82)0.864
Model 2142/2551.01.30 (0.72–2.35)0.89 (0.48–1.63)1.05 (0.56–1.95)0.970
Model 3146/2751.01.03 (0.57–1.87)0.92 (0.50–1.67)0.95 (0.52–1.71)0.759
Model 4150/2711.01.16 (0.64–2.10)0.93 (0.52–1.69)1.03 (0.58–1.85)0.984
Premenopausal women
DHEAS
Model 1188/3361.00.35 (0.20–0.61)0.61 (0.37–1.01)0.84 (0.52–1.37)0.341
Model 2142/2551.00.28 (0.14–0.56)0.50 (0.28–0.92)0.80 (0.43–1.48)0.777
Model 3181/3281.00.37 (0.21–0.66)0.58 (0.35–0.99)0.87 (0.53–1.45)0.377
Model 4153/2661.00.31 (0.16–0.59)0.58 (0.33–1.02)0.80 (0.46–1.40)0.562
Postmenopausal women
DHEA
Model 1269/5711.00.80 (0.50–1.26)1.15 (0.75–1.75)1.25 (0.82–1.89)0.154
Model 2249/5281.00.80 (0.50–1.29)1.13 (0.72–1.76)1.05 (0.66–1.67)0.590
Model 3267/5641.00.83 (0.52–1.33)1.18 (0.77–1.81)1.30 (0.85–2.00)0.132
Model 4264/5611.00.83 (0.52–1.32)1.21 (0.79–1.85)1.29 (0.84–2.00)0.127
Postmenopausal women
DHEAS
Model 1359/7451.01.40 (0.95–2.07)1.50 (1.01–2.22)1.75 (1.19–2.57)0.006
Model 2249/5281.01.59 (0.96–2.63)1.74 (1.05–2.87)2.04 (1.23–3.40)0.019
Model 3356/7351.01.43 (0.90–2.00)1.50 (1.01–2.23)1.70 (1.14–2.52)0.009
Model 4276/5781.01.61 (1.01–2.56)1.57 (0.99–2.49)2.00 (1.25–3.12)0.028
  • Note: Model 1: Adjusted for age and BMI at blood draw (continuous), history of benign breast disorder (no, yes), family history of breast cancer (no, yes), smoking status (never, past, current smoker), alcohol consumption (g/d), time of day of blood draw, and menopausal hormone therapy (never, previous use; postmenopausal women only). Model 2: as Model 1, with addition of DHEA/S (log-transformed, continuous), respectively. Model 3: as Model 1, with addition of percentage mammographic breast density by STRATUS (square root-transformed, continuous). Model 4: as Model 1, with addition of total testosterone (ng/mL, continuous).

  • aDHEA premenopausal: 1st: <5.2 ng/mL, 2nd: 5.2–18.6, 3rd: 18.6–34.7, 4th: ≥34.8; postmenopausal: 1st: <2.6 ng/mL, 2nd: 2.6–9.0, 3rd: 9.0–22.3, 4th: ≥22.4. DHEAS premenopausal: 1st: <1.4 μg/mL, 2nd: 1.4–1.9, 3rd: 1.9–2.7, 4th: ≥2.8; postmenopausal: 1st: <0.7 μg/mL, 2nd: 0.7–1.2, 3rd: 1.2–1.8, 4th: ≥1.9.

  • bP value based on Wald test of natural log-transformed hormone, treated as a continuous variable.